Inventor · disambiguated record
Olaf Joens
Also filed as: JOENS OLAF
9 granted patents·40 citations·filing 2005–2018
85Inventor score
Top patents by PatentIndex Score
9 records- 0190US8980894B2Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failureDAEMMGEN JUERGEN·Filed 2009·Granted Mar 17, 2015·16 cites·14 claims
- 0288US10537588B2Use of pimobendan for the reduction of heart size in mammals suffering from heart failureBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2018·Granted Jan 21, 2020·6 cites·17 claims
- 0385US10537570B2Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve diseaseBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2017·Granted Jan 21, 2020·4 cites·24 claims
- 0484US10117869B2PDE III inhibitors for treatment of asymptomatic heart failureDAEMMGEN JUERGEN·Filed 2013·Granted Nov 6, 2018·4 cites·15 claims
- 0584US9889148B2Use of pimobendan for the reduction of heart size in mammals suffering from heart failureDAEMMGEN JUERGEN·Filed 2014·Granted Feb 13, 2018·7 cites·27 claims
- 0677US9463199B2Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failureDAEMMGEN JUERGEN·Filed 2005·Granted Oct 11, 2016·3 cites·12 claims
- 0768US11413285B2PDE III inhibitors for treatment of asymptomatic heart failureBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2018·Granted Aug 16, 2022·0 cites·18 claims
- 0862US12011441B2Pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve diseaseBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2018·Granted Jun 18, 2024·0 cites·19 claims
- 0959US8664252B2Phosphodiesterase type III (PDE III) inhibitors or CA2+-sensitizing agents for the treatment of hypertrophic cardiomyopathyDAEMMGEN JUERGEN·Filed 2009·Granted Mar 4, 2014·0 cites·15 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →